X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (82) 82
humans (80) 80
male (65) 65
female (61) 61
pharmacology & pharmacy (58) 58
adult (57) 57
middle aged (51) 51
pharmacokinetics (35) 35
aged (25) 25
oncology (25) 25
dose-response relationship, drug (22) 22
pharmacodynamics (20) 20
young adult (20) 20
cross-over studies (19) 19
adolescent (17) 17
neoplasms - drug therapy (16) 16
animals (15) 15
drug administration schedule (15) 15
apixaban (14) 14
dosage and administration (14) 14
drug interactions (14) 14
administration, oral (13) 13
research (13) 13
area under curve (12) 12
dapagliflozin (12) 12
glucose (12) 12
hypoglycemic agents - pharmacokinetics (12) 12
internal medicine (12) 12
benzhydryl compounds (11) 11
double-blind (11) 11
pyrazoles - pharmacokinetics (11) 11
pyridones - pharmacokinetics (11) 11
type 2 diabetes (11) 11
dextrose (10) 10
endocrinology & metabolism (10) 10
glucosides - pharmacokinetics (10) 10
inadequate glycemic control (10) 10
thromboprophylaxis (10) 10
medicine & public health (9) 9
pharmacology/toxicology (9) 9
double-blind method (8) 8
drug dosages (8) 8
factor xa inhibitor (8) 8
hypoglycemic agents - administration & dosage (8) 8
safety (8) 8
sglt2 inhibitor (8) 8
therapy (8) 8
trial (8) 8
aged, 80 and over (7) 7
analysis (7) 7
anticoagulants (7) 7
cancer (7) 7
chemotherapy (7) 7
chromatography, high pressure liquid (7) 7
drug evaluation (7) 7
factor xa inhibitors - pharmacokinetics (7) 7
healthy volunteers (7) 7
in-vitro (7) 7
knee replacement (7) 7
metabolites (7) 7
mice (7) 7
neoplasms - metabolism (7) 7
pharmacotherapy (7) 7
plasma (7) 7
potent (7) 7
veterinary sciences (7) 7
antineoplastic agents - pharmacokinetics (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
buthionine sulfoximine (6) 6
chemistry, analytical (6) 6
diabetes (6) 6
diabetes mellitus, type 2 - drug therapy (6) 6
enoxaparin (6) 6
expression (6) 6
fluoroquinolones (6) 6
glutathione - metabolism (6) 6
glutathione transferase - metabolism (6) 6
half-life (6) 6
health aspects (6) 6
healthy-subjects (6) 6
melphalan (6) 6
metabolic clearance rate (6) 6
pharmacology (6) 6
pyrazoles - pharmacology (6) 6
pyridones - pharmacology (6) 6
rivaroxaban (6) 6
saxagliptin (6) 6
sodium-glucose transporter 2 - antagonists & inhibitors (6) 6
studies (6) 6
adamantane - analogs & derivatives (5) 5
anti-infective agents - administration & dosage (5) 5
bioavailability (5) 5
care and treatment (5) 5
cyto-toxicity (5) 5
factor xa inhibitors (5) 5
fluorouracil - pharmacokinetics (5) 5
glucosides - administration & dosage (5) 5
hypoglycemic agents - adverse effects (5) 5
infusions, intravenous (5) 5
international normalized ratio (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2011, Volume 13, Issue 1, pp. 47 - 54
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 432 - 444
Aim(s)This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose... 
sodium‐glucose transporter 2 | type 2 diabetes mellitus | glucuronosyltransferase | UGT1A9 | dapagliflozin | renal insufficiency | Renal insufficiency | Sodium-glucose transporter 2 | Type 2 diabetes mellitus | Dapagliflozin | Glucuronosyltransferase | CLEARANCE | METFORMIN | SELECTIVE SGLT2 INHIBITOR | MONOTHERAPY | sodium-glucose transporter 2 | INADEQUATE GLYCEMIC CONTROL | GLOMERULAR-FILTRATION-RATE | PHARMACOKINETICS | GLUCOSE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | Humans | Middle Aged | Male | Glucosides - pharmacokinetics | Liver - physiopathology | Kidney Function Tests | Dose-Response Relationship, Drug | Young Adult | Kidney - metabolism | Liver - drug effects | Adult | Female | Glucosides - therapeutic use | Glucosides - adverse effects | Glycosuria - urine | Kidney - physiopathology | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Hypoglycemic Agents - pharmacokinetics | Kidney - drug effects | Benzhydryl Compounds | Blood Glucose - analysis | Liver - metabolism | Diabetes Mellitus, Type 2 - urine | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Physiological aspects | Care and treatment | Index Medicus | Pharmacokinetic Dynamic Relationships
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2013, Volume 15, Issue 3, pp. 280 - 283
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 05/2018, Volume 84, Issue 5, pp. 876 - 887
AimsThe aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa... 
pharmacokinetics | Japanese | factor XIa inhibition | pharmacodynamics | anticoagulation | TARGET | COAGULATION-FACTOR XI | EVENTS | VENOUS THROMBOSIS | RISK | RATIO | DEFICIENCY | PHARMACOLOGY & PHARMACY | ISCHEMIC-STROKE | Index Medicus | Clinical Trials
Journal Article
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2013, Volume 35, Issue 8, pp. 1211 - 1222.e2
Journal Article
Advances in Therapy, ISSN 0741-238X, 2/2012, Volume 29, Issue 2, pp. 163 - 177
Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with type 2 diabetes mellitus (T2DM). The... 
dapagliflozin | pharmacodynamics | Rheumatology | simvastatin | sodium glucose co-transporter-2 | Internal Medicine | Oncology | digoxin | warfarin | type 2 diabetes | Medicine & Public Health | pharmacokinetics | valsartan | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SELECTIVE SGLT2 INHIBITOR | HEALTHY-SUBJECTS | HUMANS | INADEQUATE GLYCEMIC CONTROL | DIABETES-MELLITUS | POTENT | HYPERGLYCEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TYPE-2 | ASSOCIATION | Hypoglycemic Agents - pharmacokinetics | Benzhydryl Compounds | Valsartan | Valine - pharmacokinetics | Humans | Middle Aged | Valine - analogs & derivatives | Male | Glucosides - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Anti-Arrhythmia Agents - pharmacokinetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | Anticholesteremic Agents - pharmacokinetics | Drug Interactions | Adult | Female | Anticoagulants - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Tetrazoles - pharmacokinetics | Type 2 diabetes | Warfarin | Digoxin | Simvastatin | Drug interactions | Anticoagulants (Medicine) | Glucose | Dextrose | Antilipemic agents | Cardiac glycosides | Blood circulation disorders | Cardiotonic agents | Cardiac patients | Diabetes | Heart diseases | Health technology assessment
Journal Article